IDEXX Laboratories, Inc. (IDXX) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Elite profitability ⢠Strong cash flow ⢠Rich valuation IDXX delivers elite profitability and strong cash generation, but moderate liquidity, rising leverage, and a very rich valuation make the stock highly dependent on sustained top-tier execution.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Resistance Capping ⢠Weak Momentum Support Level: $550.00 Resistance Level: $568-$572 Over the last month, IDXX has staged a choppy rebound above $550 support, but repeated stalls at $568â$572 show the recovery is still unconfirmed.
Sentiment & News
Key News Insights: ⢠Product expansion ⢠AI adoption ⢠Investor outreach IDEXX is expanding its diagnostics portfolio and AI/software capabilities while stepping up investor outreach, but recent stock weakness shows the market remains cautious.
AI Summary
IDXX remains a best-in-class, cash-generative diagnostics franchise, but the investment case now hinges on proving sustained double-digit growth and margin expansion to justify its premium multiple, making valuation compression the key risk if growth merely stays âgoodâ instead of excellent.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |